Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gene-edited iPSC-derived natural killer cells
- Development stage
- Preclinical
- Lead developer
- Cytovia
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Cytovia Therapeutics is developing gene-edited induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells as an allogeneic, off-the-shelf cell therapy for the treatment of solid tumors, primarily hepatocellular carcinoma (HCC). Utilizing TALEN gene-editing technology, these cells are engineered with specific functional enhancements to overcome the limitations of conventional NK cell therapies. Key modifications include the knock-in of Interleukin-15 (IL-15) to promote cell persistence and metabolic fitness, and the knock-out of the Transforming Growth Factor-beta Receptor type 2 (TGFβR2) to render the cells resistant to the immunosuppressive effects of TGF-beta within the tumor microenvironment. This platform aims to provide a scalable and potent immunotherapy that can be used as a monotherapy or in combination with multi-specific antibodies to enhance tumor targeting.
- Other names
- gene-edited iNK cellsTALEN gene-edited iPSC-derived NK cellsCytovia iPSC-derived NK cells
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)TGFBR2 (TGF-β receptor type 2)GPC3 (Glypican-3)
Beyond the preview
Go deeper on gene-edited iPSC-derived natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gene-edited iPSC-derived natural killer cells.